Climb Bio reports Q3 EPS (13c) vs (15c) last year

Cash Position: Cash, cash equivalents and marketable securities were $217.9M as of September 30 , as compared to $106.8M as of December 31, 2023. Cash is expected to fund operations through 2027..”We have had a very productive third quarter, successfully completing the rebranding and transition of Climb Bio (CLYM) into a leading immune-mediated diseases company,” said Aoife Brennan, President and CEO of Climb Bio. “At our recent investor event, we outlined our development strategy and the broad potential of budoprutug. We have now received U.S. Food and Drug Administration clearance of our IND for our Phase 1b clinical trial of budoprutug in SLE and expanded our board and management team with the appointment of Dr. Doug Williams as Climb Bio’s new board Chair and Dr. Gary Hao as Vice President of CMC. With a strong financial position and continued progress towards building our management team, we believe we are well-positioned to develop improved treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases.”